Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2023

Open Access 01-12-2023 | Antidepressant Drugs | Review

α7 Nicotinic acetylcholine receptor: a key receptor in the cholinergic anti-inflammatory pathway exerting an antidepressant effect

Authors: Huiyang Liu, Xiaomei Zhang, Peng Shi, Jiyuan Yuan, Qiang Jia, Chao Pi, Tao Chen, Linjin Xiong, Jinglin Chen, Jia Tang, Ruxu Yue, Zerong Liu, Hongping Shen, Ying Zuo, Yumeng Wei, Ling Zhao

Published in: Journal of Neuroinflammation | Issue 1/2023

Login to get access

Abstract

Depression is a common mental illness, which is related to monoamine neurotransmitters and the dysfunction of the cholinergic, immune, glutamatergic, and neuroendocrine systems. The hypothesis of monoamine neurotransmitters is one of the commonly recognized pathogenic mechanisms of depression; however, the drugs designed based on this hypothesis have not achieved good clinical results. A recent study demonstrated that depression and inflammation were strongly correlated, and the activation of alpha7 nicotinic acetylcholine receptor (α7 nAChR)-mediated cholinergic anti-inflammatory pathway (CAP) in the cholinergic system exhibited good therapeutic effects against depression. Therefore, anti-inflammation might be a potential direction for the treatment of depression. Moreover, it is also necessary to further reveal the key role of inflammation and α7 nAChR in the pathogenesis of depression. This review focused on the correlations between inflammation and depression as well-discussed the crucial role of α7 nAChR in the CAP.
Literature
1.
2.
3.
4.
Ménard C, Hodes GE, Russo SJ. Pathogenesis of depression: insights from human and rodent studies. Neuroscience. 2016;321:138–62.PubMedCrossRef
5.
Lu X, Ce Q, Jin L, Zheng J, Sun M, Tang X, et al. Deoiled sunflower seeds ameliorate depression by promoting the production of monoamine neurotransmitters and inhibiting oxidative stress. Food Funct. 2021;12:573–86.PubMedCrossRef
6.
Dong Z, Xie Q, Xu F, Shen X, Hao Y, Li J, et al. Neferine alleviates chronic stress-induced depression by regulating monoamine neurotransmitter secretion and gut microbiota structure. Front Pharmacol. 2022;13: 974949.PubMedPubMedCentralCrossRef
7.
Steingard RJ, Yurgelun-Todd DA, Hennen J, Moore JC, Moore CM, Vakili K, et al. Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy. Biol Psychiatry. 2000;48:1053–61.PubMedCrossRef
8.
Charles HC, Lazeyras F, Krishnan KR, Boyko OB, Payne M, Moore D. Brain choline in depression: in vivo detection of potential pharmacodynamic effects of antidepressant therapy using hydrogen localized spectroscopy. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18:1121–7.PubMedCrossRef
9.
Arias HR, Targowska-Duda KM, García-Colunga J, Ortells MO. Is the antidepressant activity of selective serotonin reuptake inhibitors mediated by nicotinic acetylcholine receptors? Molecules. 2021;26:2149.PubMedPubMedCentralCrossRef
10.
11.
12.
Duan C-M, Zhang J-R, Wan T-F, Wang Y, Chen H-S, Liu L. SRT2104 attenuates chronic unpredictable mild stress-induced depressive-like behaviors and imbalance between microglial M1 and M2 phenotypes in the mice. Behav Brain Res. 2020;378: 112296.PubMedCrossRef
13.
Cui W, Ning Y, Hong W, Wang J, Liu Z, Li MD. Crosstalk between inflammation and glutamate system in depression: signaling pathway and molecular biomarkers for ketamine’s antidepressant effect. Mol Neurobiol. 2019;56:3484–500.PubMedCrossRef
14.
15.
Kim E-Y, Choi J-E, Kim M, Hong J, Park Y. N-3 PUFA have antidepressant-like effects via improvement of the HPA-axis and neurotransmission in rats exposed to combined stress. Mol Neurobiol. 2020;57:3860–74.PubMedCrossRef
16.
17.
MacQueen G, Santaguida P, Keshavarz H, Jaworska N, Levine M, Beyene J, et al. Systematic review of clinical practice guidelines for failed antidepressant treatment response in major depressive disorder, dysthymia, and subthreshold depression in adults. Can J Psychiatry. 2017;62:11–23.PubMedCrossRef
18.
19.
Ballinger EC, Ananth M, Talmage DA, Role LW. Basal forebrain cholinergic circuits and signaling in cognition and cognitive decline. Neuron. 2016;91:1199–218.PubMedPubMedCentralCrossRef
20.
Picciotto MR, Higley MJ, Mineur YS. Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron. 2012;76:116–29.PubMedPubMedCentralCrossRef
21.
Ventura-Bort C, Wirkner J, Wendt J, Hamm AO, Weymar M. Establishment of emotional memories is mediated by vagal nerve activation: evidence from noninvasive taVNS. J Neurosci. 2021;41:7636–48.PubMedPubMedCentralCrossRef
22.
23.
Mineur YS, Obayemi A, Wigestrand MB, Fote GM, Calarco CA, Li AM, et al. Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior. Proc Natl Acad Sci USA. 2013;110:3573–8.PubMedPubMedCentralCrossRef
24.
Xu ZQ, Zhang WJ, Su DF, Zhang GQ, Miao CY. Cellular responses and functions of α7 nicotinic acetylcholine receptor activation in the brain: a narrative review. Ann Transl Med. 2021;9(6):509.PubMedPubMedCentralCrossRef
25.
Liu RT, Rowan-Nash AD, Sheehan AE, Walsh RFL, Sanzari CM, Korry BJ, et al. Reductions in anti-inflammatory gut bacteria are associated with depression in a sample of young adults. Brain Behav Immun. 2020;88:308–24.PubMedPubMedCentralCrossRef
26.
Liu C-H, Yang M-H, Zhang G-Z, Wang X-X, Li B, Li M, et al. Neural networks and the anti-inflammatory effect of transcutaneous auricular vagus nerve stimulation in depression. J Neuroinflamm. 2020;17:54.CrossRef
27.
Han B, Li X, Hao J. The cholinergic anti-inflammatory pathway: an innovative treatment strategy for neurological diseases. Neurosci Biobehav Rev. 2017;77:358–68.PubMedCrossRef
28.
Colasanto M, Madigan S, Korczak DJ. Depression and inflammation among children and adolescents: a meta-analysis. J Affect Disord. 2020;277:940–8.PubMedCrossRef
29.
Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun. 2015;49:206–15.PubMedPubMedCentralCrossRef
30.
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446–57.PubMedCrossRef
31.
Osimo EF, Baxter LJ, Lewis G, Jones PB, Khandaker GM. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol Med. 2019;49:1958–70.PubMedPubMedCentralCrossRef
32.
Green C, Shen X, Stevenson AJ, Conole ELS, Harris MA, Barbu MC, et al. Structural brain correlates of serum and epigenetic markers of inflammation in major depressive disorder. Brain Behav Immun. 2021;92:39–48.PubMedPubMedCentralCrossRef
33.
Sakamoto S, Zhu X, Hasegawa Y, Karma S, Obayashi M, Alway E, et al. Inflamed brain: targeting immune changes and inflammation for treatment of depression. Psychiatry Clin Neurosci. 2021;75:304–11.PubMedPubMedCentralCrossRef
34.
Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16:22–34.PubMedPubMedCentralCrossRef
35.
Köhler-Forsberg O, Lydholm CN, Hjorthøj C, Nordentoft M, Mors O, Benros ME. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatr Scand. 2019;139:404–19.PubMedCrossRef
36.
Dionisie V, Filip GA, Manea MC, Manea M, Riga S. The anti-inflammatory role of SSRI and SNRI in the treatment of depression: a review of human and rodent research studies. Inflammopharmacology. 2021;29:75–90.PubMedCrossRef
37.
Jiang C, Lin WJ, Sadahiro M, et al. VGF function in depression and antidepressant efficacy. Mol Psychiatry. 2018;23(7):1632–42.PubMedCrossRef
38.
Park H-J, Shim H-S, An K, Starkweather A, Kim KS, Shim I. IL-4 inhibits IL-1β-induced depressive-like behavior and central neurotransmitter alterations. Mediat Inflamm. 2015;2015: 941413.CrossRef
39.
Craig CF, Filippone RT, Stavely R, Bornstein JC, Apostolopoulos V, Nurgali K. Neuroinflammation as an etiological trigger for depression comorbid with inflammatory bowel disease. J Neuroinflamm. 2022;19(1):4.CrossRef
40.
Delgado I, Huet L, Dexpert S, Beau C, Forestier D, Ledaguenel P, et al. Depressive symptoms in obesity: relative contribution of low-grade inflammation and metabolic health. Psychoneuroendocrinology. 2018;91:55–61.PubMedCrossRef
41.
Arteaga-Henríquez G, Simon MS, Burger B, Weidinger E, Wijkhuijs A, Arolt V, et al. Low-grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD patients: a systematic review of the literature in combination with an analysis of experimental data collected in the EU-MOODINFLAME consortium. Front Psychiatry. 2019;10:458.PubMedPubMedCentralCrossRef
42.
Cardinal P, Monchaux de Oliveira C, Sauvant J, Foury A, Darnaudéry M, Vancassel S, et al. A new experimental design to study inflammation-related versus non-inflammation-related depression in mice. J Neuroinflamm. 2021;18:290.CrossRef
43.
Tayab MA, Islam MN, Chowdhury KAA, Tasnim FM. Targeting neuroinflammation by polyphenols: a promising therapeutic approach against inflammation-associated depression. Biomed Pharmacother. 2022;147: 112668.PubMedCrossRef
44.
Kronsten VT, Tranah TH, Pariante C, Shawcross DL. Gut-derived systemic inflammation as a driver of depression in chronic liver disease. J Hepatol. 2022;76:665–80.PubMedCrossRef
45.
Roman M, Irwin MR. Novel neuroimmunologic therapeutics in depression: a clinical perspective on what we know so far. Brain Behav Immun. 2020;83:7–21.PubMedCrossRef
46.
47.
Felger JC. Role of inflammation in depression and treatment implications. Handb Exp Pharmacol. 2019;250:255–86.PubMedCrossRef
48.
49.
50.
Brites D, Fernandes A. Neuroinflammation and depression: microglia activation, extracellular microvesicles and microRNA dysregulation. Front Cell Neurosci. 2015;9:476.PubMedPubMedCentralCrossRef
51.
Sun Y, Koyama Y, Shimada S. Inflammation from peripheral organs to the brain: how does systemic inflammation cause neuroinflammation? Front Aging Neurosci. 2022;14: 903455.PubMedPubMedCentralCrossRef
52.
McKim DB, Weber MD, Niraula A, Sawicki CM, Liu X, Jarrett BL, et al. Microglial recruitment of IL-1β-producing monocytes to brain endothelium causes stress-induced anxiety. Mol Psychiatry. 2018;23:1421–31.PubMedCrossRef
53.
Han Y, Ding L, Cheng X, Zhao M, Zhao T, Guo L, et al. Hypoxia augments cerebral inflammation in a dextran sulfate sodium-induced colitis mouse model. Front Cell Neurosci. 2020;14: 611764.PubMedPubMedCentralCrossRef
54.
Nedic Erjavec G, Sagud M, Nikolac Perkovic M, Svob Strac D, Konjevod M, Tudor L, et al. Depression: biological markers and treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2021;105: 110139.PubMedCrossRef
55.
Schiltz JC, Sawchenko PE. Signaling the brain in systemic inflammation: the role of perivascular cells. Front Biosci. 2003;8:s1321-1329.PubMedCrossRef
56.
Corsi-Zuelli FMDG, Brognara F, Quirino GFDS, Hiroki CH, Fais RS, Del-Ben CM, et al. Neuroimmune interactions in schizophrenia: focus on vagus nerve stimulation and activation of the alpha-7 nicotinic acetylcholine receptor. Front Immunol. 2017;8:618. PubMedPubMedCentralCrossRef
57.
58.
Troubat R, Barone P, Leman S, Desmidt T, Cressant A, Atanasova B, et al. Neuroinflammation and depression: a review. Eur J Neurosci. 2021;53:151–71.PubMedCrossRef
59.
Sun Y, Zhou Y-Q, Liu Y-K, Zhang H-Q, Hou G-G, Meng Q-G, et al. Potential anti-neuroinflammatory NF-кB inhibitors based on 3,4-dihydronaphthalen-1(2H)-one derivatives. J Enzyme Inhib Med Chem. 2020;35:1631–40.PubMedPubMedCentralCrossRef
60.
Pike AF, Szabò I, Veerhuis R, Bubacco L. The potential convergence of NLRP3 inflammasome, potassium, and dopamine mechanisms in Parkinson’s disease. NPJ Parkinsons Dis. 2022;8:32.PubMedPubMedCentralCrossRef
61.
Di Lucente J, Nguyen HM, Wulff H, Jin LW, Maezawa I. The voltage-gated potassium channel Kv1.3 is required for microglial pro-inflammatory activation in vivo. Glia. 2018;66(9):1881–95.PubMedPubMedCentralCrossRef
62.
Hashioka S, Miyaoka T, Wake R, Furuya M, Horiguchi J. Glia: an important target for anti-inflammatory and antidepressant activity. Curr Drug Targets. 2013;14(11):1322–8.PubMedCrossRef
63.
Jo WK, Zhang Y, Emrich HM, Dietrich DE. Glia in the cytokine-mediated onset of depression: fine tuning the immune response. Front Cell Neurosci. 2015;9:268.PubMedPubMedCentralCrossRef
64.
Peppas S, Pansieri C, Piovani D, Danese S, Peyrin-Biroulet L, Tsantes AG, et al. The brain–gut axis: psychological functioning and inflammatory bowel diseases. J Clin Med. 2021;10:377.PubMedPubMedCentralCrossRef
65.
Han Y, Zhao T, Cheng X, Zhao M, Gong S-H, Zhao Y-Q, et al. Cortical inflammation is increased in a DSS-induced colitis mouse model. Neurosci Bull. 2018;34:1058–66.PubMedPubMedCentralCrossRef
66.
Wang H, Yang Y, Yang S, Ren S, Feng J, Liu Y, et al. Ginsenoside Rg1 ameliorates neuroinflammation via suppression of connexin43 ubiquitination to attenuate depression. Front Pharmacol. 2021;12: 709019.PubMedPubMedCentralCrossRef
67.
68.
Huang Y, Mao Z, Zhang Z, et al. Connexin43 contributes to inflammasome activation and lipopolysaccharide-initiated acute renal injury via modulation of intracellular oxidative status. Antioxid Redox Signal. 2019;31(16):1194–212.PubMedCrossRef
69.
Wang X, Feng L, Xin M, et al. Mechanisms underlying astrocytic connexin-43 autophagy degradation during cerebral ischemia injury and the effect on neuroinflammation and cell apoptosis. Biomed Pharmacother. 2020;127: 110125.PubMedCrossRef
70.
Allen J, Romay-Tallon R, Brymer KJ, Caruncho HJ, Kalynchuk LE. Mitochondria and mood: mitochondrial dysfunction as a key player in the manifestation of depression. Front Neurosci. 2018;12:386.PubMedPubMedCentralCrossRef
71.
Calingasan NY, Ho DJ, Wille EJ, Campagna MV, Ruan J, Dumont M, et al. Influence of mitochondrial enzyme deficiency on adult neurogenesis in mouse models of neurodegenerative diseases. Neuroscience. 2008;153:986–96.PubMedCrossRef
72.
Adzic M, Brkic Z, Bulajic S, Mitic M, Radojcic MB. Antidepressant action on mitochondrial dysfunction in psychiatric disorders. Drug Dev Res. 2016;77(7):400–6.PubMedCrossRef
73.
Mozafari H, Amiri S, Mehr SE, Momeny M, Amini-Khoei H, Bijani S, et al. Minocycline attenuates depressive-like behaviors in mice treated with the low dose of intracerebroventricular streptozotocin; the role of mitochondrial function and neuroinflammation. Mol Biol Rep. 2020;47:6143–53.PubMedCrossRef
74.
Haj-Mirzaian A, Amiri S, Amini-Khoei H, Haj-Mirzaian A, Hashemiaghdam A, Ramezanzadeh K, et al. Involvement of NO/NMDA-R pathway in the behavioral despair induced by amphetamine withdrawal. Brain Res Bull. 2018;139:81–90.PubMedCrossRef
75.
Beheshti F, Hashemzehi M, Hosseini M, Marefati N, Memarpour S. Inducible nitric oxide synthase plays a role in depression- and anxiety-like behaviors chronically induced by lipopolysaccharide in rats: evidence from inflammation and oxidative stress. Behav Brain Res. 2020;392: 112720.PubMedCrossRef
76.
Dutheil S, Ota KT, Wohleb ES, Rasmussen K, Duman RS. High-fat diet induced anxiety and anhedonia: impact on brain homeostasis and inflammation. Neuropsychopharmacology. 2016;41(7):1874–87.PubMedPubMedCentralCrossRef
77.
Spielman LJ, Gibson DL, Klegeris A. Unhealthy gut, unhealthy brain: the role of the intestinal microbiota in neurodegenerative diseases. Neurochem Int. 2018;120:149–63.PubMedCrossRef
78.
Hurtado-Alvarado G, Domínguez-Salazar E, Pavon L, Velázquez-Moctezuma J, Gómez-González B. Blood–brain barrier disruption induced by chronic sleep loss: low-grade inflammation may be the link. J Immunol Res. 2016;2016:4576012.PubMedPubMedCentralCrossRef
79.
Nouri A, Hashemzadeh F, Soltani A, Saghaei E, Amini-Khoei H. Progesterone exerts antidepressant-like effect in a mouse model of maternal separation stress through mitigation of neuroinflammatory response and oxidative stress. Pharm Biol. 2020;58:64–71.PubMedCrossRef
80.
Moradi-Marjaneh R, Hassanian SM, Mehramiz M, Rezayi M, Ferns GA, Khazaei M, et al. Reactive oxygen species in colorectal cancer: the therapeutic impact and its potential roles in tumor progression via perturbation of cellular and physiological dysregulated pathways. J Cell Physiol. 2019;234:10072–9.PubMedCrossRef
81.
Lorigooini Z, Boroujeni SN, Sayyadi-Shahraki M, Rahimi-Madiseh M, Bijad E, Amini-Khoei H. Limonene through attenuation of neuroinflammation and nitrite level exerts antidepressant-like effect on mouse model of maternal separation stress. Behav Neurol. 2021;2021:8817309.PubMedPubMedCentralCrossRef
82.
83.
Niciu MJ, Ionescu DF, Richards EM, Zarate CA. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm (Vienna). 2014;121:907–24.PubMedCrossRef
84.
85.
Ancelin ML, Scali J, Norton J, et al. Heterogeneity in HPA axis dysregulation and serotonergic vulnerability to depression. Psychoneuroendocrinology. 2017;77:90–4.PubMedCrossRef
86.
Keller J, Gomez R, Williams G, Lembke A, Lazzeroni L, Murphy GM, et al. HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition. Mol Psychiatry. 2017;22:527–36.PubMedCrossRef
87.
Wang YT, Wang XL, Feng ST, Chen NH, Wang ZZ, Zhang Y. Novel rapid-acting glutamatergic modulators: targeting the synaptic plasticity in depression. Pharmacol Res. 2021;171: 105761.PubMedCrossRef
88.
89.
90.
Höglund E, Øverli Ø, Winberg S. Tryptophan metabolic pathways and brain serotonergic activity: a comparative review. Front Endocrinol (Lausanne). 2019;10:158.PubMedCrossRef
91.
92.
Hsu C-N, Tain Y-L. Developmental programming and reprogramming of hypertension and kidney disease: impact of tryptophan metabolism. IJMS. 2020;21:8705.PubMedPubMedCentralCrossRef
93.
94.
Halaris A. Inflammation and depression but where does the inflammation come from? Curr Opin Psychiatry. 2019;32:422–8.PubMedCrossRef
95.
Dean J, Keshavan M. The neurobiology of depression: an integrated view. Asian J Psychiatr. 2017;27:101–11.PubMedCrossRef
96.
St’astný F, Lisý V, Mares V, Lisá V, Balcar VJ, Santamaría A. Quinolinic acid induces NMDA receptor-mediated lipid peroxidation in rat brain microvessels. Redox Rep. 2004;9:229–33.PubMedCrossRef
97.
98.
Fukuwatari T. Possibility of amino acid treatment to prevent the psychiatric disorders via modulation of the production of tryptophan metabolite kynurenic acid. Nutrients. 2020;12:1403.PubMedPubMedCentralCrossRef
99.
Pocivavsek A, Wu H-Q, Potter MC, Elmer GI, Pellicciari R, Schwarcz R. Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory. Neuropsychopharmacology. 2011;36:2357–67.PubMedPubMedCentralCrossRef
100.
Kruse JL, Cho JH-J, Olmstead R, Hwang L, Faull K, Eisenberger NI, et al. Kynurenine metabolism and inflammation-induced depressed mood: a human experimental study. Psychoneuroendocrinology. 2019;109: 104371.PubMedPubMedCentralCrossRef
101.
Kazumori H, Ishihara S, Rumi MA, Ortega-Cava CF, Kadowaki Y, Kinoshita Y. Transforming growth factor-alpha directly augments histidine decarboxylase and vesicular monoamine transporter 2 production in rat enterochromaffin-like cells. Am J Physiol Gastrointest Liver Physiol. 2004;286(3):G508–14.PubMedCrossRef
102.
103.
104.
Clarke M, Razmjou S, Prowse N, Dwyer Z, Litteljohn D, Pentz R, et al. Ketamine modulates hippocampal neurogenesis and pro-inflammatory cytokines but not stressor induced neurochemical changes. Neuropharmacology. 2017;112:210–20.PubMedCrossRef
105.
106.
Elgueta D, Aymerich MS, Contreras F, Montoya A, Celorrio M, Rojo-Bustamante E, et al. Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson’s disease. Neuropharmacology. 2017;113:110–23.PubMedCrossRef
107.
Elgueta D, Contreras F, Prado C, Montoya A, Ugalde V, Chovar O, et al. Dopamine receptor D3 expression is altered in CD4+ T-cells from Parkinson’s disease patients and its pharmacologic inhibition attenuates the motor impairment in a mouse model. Front Immunol. 2019;10:981.PubMedPubMedCentralCrossRef
108.
Torres-Rosas R, Yehia G, Peña G, Mishra P, del Rocio T-B, Moreno-Eutimio MA, et al. Dopamine mediates vagal modulation of the immune system by electroacupuncture. Nat Med. 2014;20:291–5.PubMedPubMedCentralCrossRef
109.
Dominguez-Meijide A, Rodriguez-Perez AI, Diaz-Ruiz C, Guerra MJ, Labandeira-Garcia JL. Dopamine modulates astroglial and microglial activity via glial renin-angiotensin system in cultures. Brain Behav Immun. 2017;62:277–90.PubMedCrossRef
110.
Campos J, Pacheco R. Involvement of dopaminergic signaling in the cross talk between the renin-angiotensin system and inflammation. Semin Immunopathol. 2020;42:681–96.PubMedPubMedCentralCrossRef
111.
Harrison PJ, Lyon L, Sartorius LJ, Burnet PWJ, Lane TA. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol. 2008;22:308–22.PubMedCrossRef
112.
Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev. 2009;61(2):105–23.PubMedCrossRef
113.
Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, et al. The cystine/glutamate antiporter system x(c)(−) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal. 2013;18:522–55.PubMedPubMedCentralCrossRef
114.
Nehser M, Dark J, Schweitzer D, Campbell M, Zwicker J, Hitt DM, et al. System Xc− antiporter inhibitors: azo-linked amino-naphthyl-sulfonate analogues of sulfasalazine. Neurochem Res. 2020;45:1375–86.PubMedCrossRef
115.
Lim JKM, Delaidelli A, Minaker SW, Zhang H-F, Colovic M, Yang H, et al. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proc Natl Acad Sci USA. 2019;116:9433–42.PubMedPubMedCentralCrossRef
116.
Haroon E, Miller AH. Inflammation effects on glutamate as a pathway to neuroprogression in mood disorders. Mod Trends Pharmacopsychiatry. 2017;31:37–55.PubMedCrossRef
117.
118.
119.
Nedergaard M, Takano T, Hansen AJ. Beyond the role of glutamate as a neurotransmitter. Nat Rev Neurosci. 2002;3:748–55.PubMedCrossRef
120.
Haroon E, Miller AH. Inflammation effects on brain glutamate in depression: mechanistic considerations and treatment implications. Curr Top Behav Neurosci. 2017;31:173–98.PubMedCrossRef
121.
Nunes SOV, Vargas HO, Prado E, Barbosa DS, de Melo LP, Moylan S, et al. The shared role of oxidative stress and inflammation in major depressive disorder and nicotine dependence. Neurosci Biobehav Rev. 2013;37:1336–45.PubMedCrossRef
122.
Haroon E, Miller AH, Sanacora G. Inflammation, glutamate, and glia: a trio of trouble in mood disorders. Neuropsychopharmacology. 2017;42:193–215.PubMedCrossRef
123.
Jackman NA, Uliasz TF, Hewett JA, Hewett SJ. Regulation of system x(c)(−)activity and expression in astrocytes by interleukin-1β: implications for hypoxic neuronal injury. Glia. 2010;58:1806–15.PubMedPubMedCentralCrossRef
124.
Malarkey EB, Parpura V. Mechanisms of glutamate release from astrocytes. Neurochem Int. 2008;52(1–2):142–54.PubMedCrossRef
125.
Kim YK, Na KS. Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry. 2016;70:117–26.PubMedCrossRef
126.
Zhou Y, Danbolt NC. Glutamate as a neurotransmitter in the healthy brain. J Neural Transm (Vienna). 2014;121:799–817.PubMedCrossRef
127.
Haroon E, Chen X, Li Z, Patel T, Woolwine BJ, Hu XP, et al. Increased inflammation and brain glutamate define a subtype of depression with decreased regional homogeneity, impaired network integrity, and anhedonia. Transl Psychiatry. 2018;8:189.PubMedPubMedCentralCrossRef
128.
Zhou L, Wang T, Yu Y, Li M, Sun X, Song W, et al. The etiology of poststroke-depression: a hypothesis involving HPA axis. Biomed Pharmacother. 2022;151: 113146.PubMedCrossRef
129.
Makris AP, Karianaki M, Tsamis KI, Paschou SA. The role of the gut-brain axis in depression: endocrine, neural, and immune pathways. Hormones (Athens). 2021;20:1–12.PubMedCrossRef
130.
Hlavacova N, Li Y, Pehrson A, Sanchez C, Bermudez I, Csanova A, et al. Effects of vortioxetine on biomarkers associated with glutamatergic activity in an SSRI insensitive model of depression in female rats. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:332–8.PubMedCrossRef
131.
Shapero BG, Curley EE, Black CL, Alloy LB. The interactive association of proximal life stress and cumulative HPA axis functioning with depressive symptoms. Depress Anxiety. 2019;36:1089–101.PubMedCrossRef
132.
Dooley LN, Kuhlman KR, Robles TF, Eisenberger NI, Craske MG, Bower JE. The role of inflammation in core features of depression: insights from paradigms using exogenously-induced inflammation. Neurosci Biobehav Rev. 2018;94:219–37.PubMedPubMedCentralCrossRef
133.
Leonard BE. Inflammation and depression: a causal or coincidental link to the pathophysiology? Acta Neuropsychiatr. 2018;30(1):1–16.PubMedCrossRef
134.
Cernackova A, Durackova Z, Trebaticka J, Mravec B. Neuroinflammation and depressive disorder: the role of the hypothalamus. J Clin Neurosci. 2020;75:5–10.PubMedCrossRef
135.
Ahmad MH, Rizvi MA, Fatima M, Mondal AC. Pathophysiological implications of neuroinflammation mediated HPA axis dysregulation in the prognosis of cancer and depression. Mol Cell Endocrinol. 2021;520: 111093.PubMedCrossRef
136.
Pace TW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun. 2007;21(1):9–19.PubMedCrossRef
137.
138.
Wang X, Wu H, Miller AH. Interleukin 1alpha (IL-1alpha) induced activation of p38 mitogen-activated protein kinase inhibits glucocorticoid receptor function. Mol Psychiatry. 2004;9(1):65–75.PubMedCrossRef
139.
Kim Y-K, Na K-S, Myint A-M, Leonard BE. The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:277–84.PubMedCrossRef
140.
Saltiel PF, Silvershein DI. Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatr Dis Treat. 2015;11:875–88.PubMedPubMedCentral
141.
Zagrebelsky M, Korte M. Form follows function: BDNF and its involvement in sculpting the function and structure of synapses. Neuropharmacology. 2014;76(Pt C):628–38.PubMedCrossRef
142.
Zhang J-C, Yao W, Ren Q, Yang C, Dong C, Ma M, et al. Depression-like phenotype by deletion of α7 nicotinic acetylcholine receptor: Role of BDNF-TrkB in nucleus accumbens. Sci Rep. 2016;6:36705.PubMedPubMedCentralCrossRef
143.
Conroy JN, Jhaveri DJ, Coulson EJ. Fast-Trk(B)ing the mechanism of antidepressants. Neuron. 2021;109:1593–5.PubMedCrossRef
144.
Gerhard DM, Pothula S, Liu R-J, Wu M, Li X-Y, Girgenti MJ, et al. GABA interneurons are the cellular trigger for ketamine’s rapid antidepressant actions. J Clin Invest. 2020;130:1336–49.PubMedPubMedCentralCrossRef
145.
Picard N, Takesian AE, Fagiolini M, Hensch TK. NMDA 2A receptors in parvalbumin cells mediate sex-specific rapid ketamine response on cortical activity. Mol Psychiatry. 2019;24:828–38.PubMedPubMedCentralCrossRef
146.
Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science. 1999;286(5443):1358–62.PubMedCrossRef
147.
Björkholm C, Monteggia LM. BDNF—a key transducer of antidepressant effects. Neuropharmacology. 2016;102:72–9.PubMedCrossRef
148.
Castrén E, Monteggia LM. Brain-derived neurotrophic factor signaling in depression and antidepressant action. Biol Psychiatry. 2021;90:128–36.PubMedCrossRef
149.
Li J, He P, Zhang J, Li N. Orcinol glucoside improves the depressive-like behaviors of perimenopausal depression mice through modulating activity of hypothalamic-pituitary-adrenal/ovary axis and activating BDNF-TrkB-CREB signaling pathway. Phytother Res. 2021;35(10):5795–807.PubMedCrossRef
150.
Stanika RI, Pivovarova NB, Brantner CA, Watts CA, Winters CA, Andrews SB. Coupling diverse routes of calcium entry to mitochondrial dysfunction and glutamate excitotoxicity. Proc Natl Acad Sci USA. 2009;106:9854–9.PubMedPubMedCentralCrossRef
151.
Leal GC, Bandeira ID, Correia-Melo FS, et al. Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur Arch Psychiatry Clin Neurosci. 2021;271(3):577–82.PubMedCrossRef
152.
Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010;11:682–96.PubMedPubMedCentralCrossRef
153.
Wu J, Liu Q, Tang P, Mikkelsen JD, Shen J, Whiteaker P, et al. Heteromeric α7β2 nicotinic acetylcholine receptors in the brain. Trends Pharmacol Sci. 2016;37:562–74.PubMedPubMedCentralCrossRef
154.
Bondarenko V, Wells MM, Chen Q, Tillman TS, Singewald K, Lawless MJ, et al. Structures of highly flexible intracellular domain of human α7 nicotinic acetylcholine receptor. Nat Commun. 2022;13:793.PubMedPubMedCentralCrossRef
155.
156.
Li S, Li Z, Pei L, Le AD, Liu F. The α7nACh-NMDA receptor complex is involved in cue-induced reinstatement of nicotine seeking. J Exp Med. 2012;209:2141–7.PubMedPubMedCentralCrossRef
157.
Ivica J, Lape R, Jazbec V, Yu J, Zhu H, Gouaux E, et al. The intracellular domain of homomeric glycine receptors modulates agonist efficacy. J Biol Chem. 2021;296: 100387.PubMedPubMedCentralCrossRef
158.
King JR, Nordman JC, Bridges SP, Lin M-K, Kabbani N. Identification and characterization of a G protein-binding cluster in α7 nicotinic acetylcholine receptors. J Biol Chem. 2015;290:20060–70.PubMedPubMedCentralCrossRef
159.
160.
Noviello CM, Gharpure A, Mukhtasimova N, Cabuco R, Baxter L, Borek D, et al. Structure and gating mechanism of the α7 nicotinic acetylcholine receptor. Cell. 2021;184:2121-2134.e13.PubMedPubMedCentralCrossRef
161.
Basak S, Gicheru Y, Samanta A, Molugu SK, Huang W, Fuente MLD, et al. Cryo-EM structure of 5-HT3A receptor in its resting conformation. Nat Commun. 2018;9:514.PubMedPubMedCentralCrossRef
162.
Polovinkin L, Hassaine G, Perot J, Neumann E, Jensen AA, Lefebvre SN, et al. Conformational transitions of the serotonin 5-HT3 receptor. Nature. 2018;563:275–9.PubMedPubMedCentralCrossRef
163.
Targowska-Duda KM, Budzynska B, Michalak A, Wnorowski A, Loland CJ, Maj M, et al. Type I and type II positive allosteric modulators of α7 nicotinic acetylcholine receptors induce antidepressant-like activity in mice by a mechanism involving receptor potentiation but not neurotransmitter reuptake inhibition. Correlation with mTOR intracellular pathway activation. Eur Neuropsychopharmacol. 2021;52:31–47.PubMedCrossRef
164.
165.
Yoshikawa H, Kurokawa M, Ozaki N, Nara K, Atou K, Takada E, et al. Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7. Clin Exp Immunol. 2006;146:116–23.PubMedPubMedCentralCrossRef
166.
Aicher A, Heeschen C, Mohaupt M, Cooke JP, Zeiher AM, Dimmeler S. Nicotine strongly activates dendritic cell-mediated adaptive immunity: potential role for progression of atherosclerotic lesions. Circulation. 2003;107:604–11.PubMedCrossRef
167.
Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J, et al. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem. 2004;89:337–43.PubMedCrossRef
168.
Sfera A, Cummings M, Osorio C. Non-neuronal acetylcholine: the missing link between sepsis, cancer, and delirium? Front Med (Lausanne). 2015;2:56.PubMed
169.
Kawashima K, Fujii T. Expression of non-neuronal acetylcholine in lymphocytes and its contribution to the regulation of immune function. Front Biosci. 2004;9:2063–85.PubMedCrossRef
170.
Egea J, Buendia I, Parada E, Navarro E, León R, Lopez MG. Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection. Biochem Pharmacol. 2015;97:463–72.PubMedCrossRef
171.
172.
173.
Nordman JC, Phillips WS, Kodama N, Clark SG, Del Negro CA, Kabbani N. Axon targeting of the alpha 7 nicotinic receptor in developing hippocampal neurons by Gprin1 regulates growth. J Neurochem. 2014;129:649–62.PubMedPubMedCentralCrossRef
174.
175.
Sun JL, Stokoe SA, Roberts JP, Sathler MF, Nip KA, Shou J, et al. Co-activation of selective nicotinic acetylcholine receptors is required to reverse beta amyloid-induced Ca2+ hyperexcitation. Neurobiol Aging. 2019;84:166–77.PubMedPubMedCentralCrossRef
176.
Ma KG, Qian YH. Alpha 7 nicotinic acetylcholine receptor and its effects on Alzheimer’s disease. Neuropeptides. 2019;73:96–106.PubMedCrossRef
177.
Corradi J, Bouzat C. Understanding the bases of function and modulation of α7 nicotinic receptors: implications for drug discovery. Mol Pharmacol. 2016;90(3):288–99.PubMedCrossRef
178.
179.
Shao B-Z, Ke P, Xu Z-Q, Wei W, Cheng M-H, Han B-Z, et al. Autophagy plays an important role in anti-inflammatory mechanisms stimulated by alpha7 nicotinic acetylcholine receptor. Front Immunol. 2017;8:553.PubMedPubMedCentralCrossRef
180.
Hou Z, Zhou Y, Yang H, Liu Y, Mao X, Qin X, et al. Alpha7 nicotinic acetylcholine receptor activation protects against myocardial reperfusion injury through modulation of autophagy. Biochem Biophys Res Commun. 2018;500:357–64.PubMedCrossRef
181.
Hua Y, Yang B, Chen Q, Zhang J, Hu J, Fan Y. Activation of α7 nicotinic acetylcholine receptor protects against 1-methyl-4-phenylpyridinium-induced astroglial apoptosis. Front Cell Neurosci. 2019;13:507.PubMedPubMedCentralCrossRef
182.
Pu Y, Tan Y, Qu Y, Chang L, Wang S, Wei Y, et al. A role of the subdiaphragmatic vagus nerve in depression-like phenotypes in mice after fecal microbiota transplantation from Chrna7 knock-out mice with depression-like phenotypes. Brain Behav Immun. 2021;94:318–26.PubMedCrossRef
183.
Marcus MM, Björkholm C, Malmerfelt A, et al. Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study. Eur Neuropsychopharmacol. 2016;26(9):1401–11.PubMedCrossRef
184.
Zhao D, Xu X, Pan L, Zhu W, Fu X, Guo L, et al. Pharmacologic activation of cholinergic alpha7 nicotinic receptors mitigates depressive-like behavior in a mouse model of chronic stress. J Neuroinflamm. 2017;14:234.CrossRef
185.
Neves GA, Grace AA. α7 nicotinic receptor full agonist reverse basolateral amygdala hyperactivity and attenuation of dopaminergic neuron activity in rats exposed to chronic mild stress. Eur Neuropsychopharmacol. 2019;29:1343–53.PubMedPubMedCentralCrossRef
186.
Chang K-W, Zong H-F, Wang M, Rizvi MY, Neha SI, Yang W-N, et al. PNU282987 alleviates Aβ-induced anxiety and depressive-like behaviors through upregulation of α7nAChR by ERK-serotonin receptors pathway. Neurosci Lett. 2020;731: 135118.PubMedCrossRef
187.
Barik J, Wonnacott S. Indirect modulation by α7 nicotinic acetylcholine receptors of noradrenaline release in rat hippocampal slices: interaction with glutamate and GABA systems and effect of nicotine withdrawal. Mol Pharmacol. 2006;69:618–28.PubMedCrossRef
188.
Livingstone PD, Srinivasan J, Kew JNC, Dawson LA, Gotti C, Moretti M, et al. alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur J Neurosci. 2009;29:539–50.PubMedCrossRef
189.
Andreasen JT, Redrobe JP, Nielsen EØ. Combined α7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of SSR180711 and PNU-282987. Pharmacol Biochem Behav. 2012;100:624–9.PubMedCrossRef
190.
Williams DK, Wang J, Papke RL. Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations. Biochem Pharmacol. 2011;82:915–30.PubMedPubMedCentralCrossRef
191.
Sun L, Yang T, Wei N, Lu W, Jiao W, Zhou Q, et al. Pharmacological characterization of JWX-A0108 as a novel type I positive allosteric modulator of α7 nAChR that can reverse acoustic gating deficits in a mouse prepulse inhibition model. Acta Pharmacol Sin. 2019;40:737–45.PubMedCrossRef
192.
Alzarea S, Rahman S. Effects of alpha-7 nicotinic allosteric modulator PNU 120596 on depressive-like behavior after lipopolysaccharide administration in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2018;86:218–28.PubMedCrossRef
193.
Alzarea S, Rahman S. Alpha-7 nicotinic receptor allosteric modulator PNU120596 prevents lipopolysaccharide-induced anxiety, cognitive deficit and depression-like behaviors in mice. Behav Brain Res. 2019;366:19–28.PubMedCrossRef
194.
Targowska-Duda KM, Feuerbach D, Biala G, Jozwiak K, Arias HR. Antidepressant activity in mice elicited by 3-furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic acetylcholine receptor. Neurosci Lett. 2014;569:126–30.PubMedCrossRef
195.
Bertrand D, Lee C-HL, Flood D, Marger F, Donnelly-Roberts D. Therapeutic potential of α7 nicotinic acetylcholine receptors. Pharmacol Rev. 2015;67:1025–73.PubMedCrossRef
196.
Yang T, Xiao T, Sun Q, Wang K. The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials. Acta Pharm Sin B. 2017;7:611–22.PubMedPubMedCentralCrossRef
197.
Jiang Y, Li L, Tan X, Liu B, Zhang Y, Li C. miR-210 mediates vagus nerve stimulation-induced antioxidant stress and anti-apoptosis reactions following cerebral ischemia/reperfusion injury in rats. J Neurochem. 2015;134:173–81.PubMedCrossRef
198.
Wang J-Y, Zhang Y, Chen Y, Wang Y, Li S-Y, Wang Y-F, et al. Mechanisms underlying antidepressant effect of transcutaneous auricular vagus nerve stimulation on CUMS model rats based on hippocampal α7nAchR/NF-κB signal pathway. J Neuroinflamm. 2021;18:291.CrossRef
199.
Mitchell S, Vargas J, Hoffmann A. Signaling via the NFκB system. WIREs Mech Dis. 2016;8:227–41.CrossRef
200.
Zhao YX, He W, Jing XH, Liu JL, Rong PJ, Ben H, et al. Transcutaneous auricular vagus nerve stimulation protects endotoxemic rat from lipopolysaccharide-induced inflammation. Evid Based Complement Alternat Med. 2012;2012: 627023.PubMedPubMedCentralCrossRef
201.
Deng Y, Guo SL, Wei B, Gao XC, Zhou YC, Li JQ. Activation of nicotinic acetylcholine α7 receptor attenuates progression of monocrotaline-induced pulmonary hypertension in rats by downregulating the NLRP3 inflammasome. Front Pharmacol. 2019;10:128.PubMedPubMedCentralCrossRef
202.
Fu H, Shen QR, Zhao Y, et al. Activating α7nAChR ameliorates abdominal aortic aneurysm through inhibiting pyroptosis mediated by NLRP3 inflammasome. Acta Pharmacol Sin. 2022;43(10):2585–95.PubMedPubMedCentralCrossRef
203.
Yang N-N, Yang J-W, Ye Y, Huang J, Wang L, Wang Y, et al. Electroacupuncture ameliorates intestinal inflammation by activating α7nAChR-mediated JAK2/STAT3 signaling pathway in postoperative ileus. Theranostics. 2021;11:4078–89.PubMedPubMedCentralCrossRef
204.
205.
Kox M, van Velzen JF, Pompe JC, Hoedemaekers CW, van der Hoeven JG, Pickkers P. GTS-21 inhibits pro-inflammatory cytokine release independent of the Toll-like receptor stimulated via a transcriptional mechanism involving JAK2 activation. Biochem Pharmacol. 2009;78:863–72.PubMedCrossRef
206.
Decker ER, Dani JA. Calcium permeability of the nicotinic acetylcholine receptor: the single-channel calcium influx is significant. J Neurosci. 1990;10:3413–20.PubMedPubMedCentralCrossRef
207.
Suzuki T, Hide I, Matsubara A, Hama C, Harada K, Miyano K, et al. Microglial α7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role. J Neurosci Res. 2006;83:1461–70.PubMedCrossRef
208.
Brea D, Agulla J, Rodríguez-Yáñez M, Barral D, Ramos-Cabrer P, Campos F, et al. Regulatory T cells modulate inflammation and reduce infarct volume in experimental brain ischaemia. J Cell Mol Med. 2014;18:1571–9.PubMedPubMedCentralCrossRef
209.
Li P, Gan Y, Sun B-L, Zhang F, Lu B, Gao Y, et al. Adoptive regulatory T-cell therapy protects against cerebral ischemia. Ann Neurol. 2013;74:458–71.PubMedPubMedCentralCrossRef
210.
Zhou X, Yuan L, Zhao X, Hou C, Ma W, Yu H, et al. Genistein antagonizes inflammatory damage induced by β-amyloid peptide in microglia through TLR4 and NF-κB. Nutrition. 2014;30:90–5.PubMedCrossRef
211.
O’Neill LAJ. The role of MyD88-like adapters in Toll-like receptor signal transduction. Biochem Soc Trans. 2003;31:643–7.PubMedCrossRef
212.
213.
214.
Hou Y, Wang Q, Han B, Chen Y, Qiao X, Wang L. CD36 promotes NLRP3 inflammasome activation via the mtROS pathway in renal tubular epithelial cells of diabetic kidneys. Cell Death Dis. 2021;12:523.PubMedPubMedCentralCrossRef
215.
Song J-Q, Jiang L-Y, Fu C-P, Wu X, Liu Z-L, Xie L, et al. Heterozygous SOD2 deletion deteriorated chronic intermittent hypoxia-induced lung inflammation and vascular remodeling through mtROS-NLRP3 signaling pathway. Acta Pharmacol Sin. 2020;41:1197–207.PubMedPubMedCentralCrossRef
216.
Li D-J, Fu H, Tong J, Li Y-H, Qu L-F, Wang P, et al. Cholinergic anti-inflammatory pathway inhibits neointimal hyperplasia by suppressing inflammation and oxidative stress. Redox Biol. 2018;15:22–33.PubMedCrossRef
217.
Chen Q, Giedt M, Tang L, Harrison DA. Tools and methods for studying the Drosophila JAK/STAT pathway. Methods. 2014;68:160–72.PubMedCrossRef
218.
Cai B, Cai J, Luo Y, Chen C, Zhang S. The specific roles of JAK/STAT signaling pathway in sepsis. Inflammation. 2015;38:1599–608.PubMedCrossRef
219.
Li BS, Ma W, Zhang L, Barker JL, Stenger DA, Pant HC. Activation of phosphatidylinositol-3 kinase (PI-3K) and extracellular regulated kinases (Erk1/2) is involved in muscarinic receptor-mediated DNA synthesis in neural progenitor cells. J Neurosci. 2001;21:1569–79.PubMedPubMedCentralCrossRef
220.
Giese KP, Fedorov NB, Filipkowski RK, Silva AJ. Autophosphorylation at Thr286 of the alpha calcium-calmodulin kinase II in LTP and learning. Science. 1998;279:870–3.PubMedCrossRef
221.
Tai Y, Feng S, Ge R, Du W, Zhang X, He Z, et al. TRPC6 channels promote dendritic growth via the CaMKIV-CREB pathway. J Cell Sci. 2008;121:2301–7.PubMedCrossRef
222.
Nagendran T, Hardy LR. Calcium/calmodulin-dependent protein kinase IV mediates distinct features of basal and activity-dependent dendrite complexity. Neuroscience. 2011;199:548–62.PubMedCrossRef
223.
Danciu TE, Adam RM, Naruse K, Freeman MR, Hauschka PV. Calcium regulates the PI3K-Akt pathway in stretched osteoblasts. FEBS Lett. 2003;536:193–7.PubMedCrossRef
224.
Conus NM, Hemmings BA, Pearson RB. Differential regulation by calcium reveals distinct signaling requirements for the activation of Akt and p70S6k. J Biol Chem. 1998;273:4776–82.PubMedCrossRef
225.
Apáti A, Jánossy J, Brózik A, Magócsi M. Effects of intracellular calcium on cell survival and the MAPK pathway in a human hormone-dependent leukemia cell line (TF-1). Ann N Y Acad Sci. 2003;1010:70–3.PubMedCrossRef
226.
Fries GR, Saldana VA, Finnstein J, Rein T. Molecular pathways of major depressive disorder converge on the synapse. Mol Psychiatry. 2022;28:1–14.
227.
Wu H, Lu D, Jiang H, et al. Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J Neurotrauma. 2008;25(2):130–9.PubMedCrossRef
228.
Kato S, Ding J, Du K. Differential activation of CREB by Akt1 and Akt2. Biochem Biophys Res Commun. 2007;354:1061–6.PubMedCrossRef
229.
West AE, Griffith EC, Greenberg ME. Regulation of transcription factors by neuronal activity. Nat Rev Neurosci. 2002;3:921–31.PubMedCrossRef
230.
Martin M, Rehani K, Jope RS, Michalek SM. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol. 2005;6:777–84.PubMedPubMedCentralCrossRef
231.
Wang H, Brown J, Gu Z, Garcia CA, Liang R, Alard P, et al. Convergence of the mammalian target of rapamycin complex 1- and glycogen synthase kinase 3-β-signaling pathways regulates the innate inflammatory response. J Immunol. 2011;186:5217–26.PubMedCrossRef
232.
Moriguchi S, Shinoda Y, Yamamoto Y, Sasaki Y, Miyajima K, Tagashira H, et al. Stimulation of the sigma-1 receptor by DHEA enhances synaptic efficacy and neurogenesis in the hippocampal dentate gyrus of olfactory bulbectomized mice. PLoS ONE. 2013;8: e60863.PubMedPubMedCentralCrossRef
233.
Shioda N, Han F, Morioka M, Fukunaga K. Bis(1-oxy-2-pyridinethiolato)oxovanadium(IV) enhances neurogenesis via phosphatidylinositol 3-kinase/Akt and extracellular signal regulated kinase activation in the hippocampal subgranular zone after mouse focal cerebral ischemia. Neuroscience. 2008;155:876–87.PubMedCrossRef
234.
235.
Marsden WN. Synaptic plasticity in depression: molecular, cellular and functional correlates. Prog Neuropsychopharmacol Biol Psychiatry. 2013;43:168–84.PubMedCrossRef
236.
Nair S, Doh ST, Chan JY, Kong A-N, Cai L. Regulatory potential for concerted modulation of Nrf2- and Nfkb1-mediated gene expression in inflammation and carcinogenesis. Br J Cancer. 2008;99:2070–82.PubMedPubMedCentralCrossRef
237.
Koistinaho M, Koistinaho J. Role of p38 and p44/42 mitogen-activated protein kinases in microglia. Glia. 2002;40:175–83.PubMedCrossRef
238.
Youssef M, Ibrahim A, Akashi K, Hossain MS. PUFA-plasmalogens attenuate the LPS-induced nitric oxide production by inhibiting the NF-kB, p38 MAPK and JNK pathways in microglial cells. Neuroscience. 2019;397:18–30.PubMedCrossRef
239.
Lee YB, Schrader JW, Kim SU. p38 map kinase regulates TNF-alpha production in human astrocytes and microglia by multiple mechanisms. Cytokine. 2000;12:874–80.PubMedCrossRef
240.
You P, Fu S, Yu K, Xia Y, Wu H, Yang Y, et al. Scutellarin suppresses neuroinflammation via the inhibition of the AKT/NF-κB and p38/JNK pathway in LPS-induced BV-2 microglial cells. Naunyn-Schmiedeberg’s Arch Pharmacol. 2018;391:743–51.CrossRef
Metadata
Title
α7 Nicotinic acetylcholine receptor: a key receptor in the cholinergic anti-inflammatory pathway exerting an antidepressant effect
Authors
Huiyang Liu
Xiaomei Zhang
Peng Shi
Jiyuan Yuan
Qiang Jia
Chao Pi
Tao Chen
Linjin Xiong
Jinglin Chen
Jia Tang
Ruxu Yue
Zerong Liu
Hongping Shen
Ying Zuo
Yumeng Wei
Ling Zhao
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2023
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/s12974-023-02768-z

Other articles of this Issue 1/2023

Journal of Neuroinflammation 1/2023 Go to the issue

Research

Blocking interleukin-23 ameliorates neuromuscular and thymic defects in myasthenia gravis

Research

Chronic neuroinflammation during aging leads to cholinergic neurodegeneration in the mouse medial septum

Research

IFNAR signaling of neuroectodermal cells is essential for the survival of C57BL/6 mice infected with Theiler’s murine encephalomyelitis virus

Research

Transfer of patient’s peripheral blood mononuclear cells (PBMCs) disrupts blood–brain barrier and induces anti-NMDAR encephalitis: a study of novel humanized PBMC mouse model

Research

Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice

Review

Progranulin and GPNMB: interactions in endo-lysosome function and inflammation in neurodegenerative disease